Key clinical point: Women with invasive breast cancer (BC) who have germline pathogenic variants (PV) in BRCA1, BRCA2, CHEK2, or PALB2 have 2-3 times higher risk for contralateral BC than those without these PVs.
Major finding: The overall risk for contralateral BC was significantly elevated in all women with germline PV in BRCA1 (hazard ratio [HR] 2.7; P < .001), BRCA2 (HR 3.0; P < .001), and CHEK2 (HR 1.9; P = .03), and in the subset of women with estrogen receptor-negative BC and germline PV in PALB2 (HR 2.9; P = .006).
Study details: Findings are from an analysis of the CARRIERS study including 15,104 women with invasive BC who underwent ipsilateral surgery.
Disclosures: This study was supported by US National Institutes of Health grants and other sources. The authors declared serving as consultants or advisors and on speakers’ bureaus; receiving research funding, travel, accommodation expenses, or honoraria; and having other ties with several sources.
Source: Yadav S, Boddicker NJ, et al. Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J Clin Oncol. 2023 (Jan 9). Doi: 10.1200/JCO.22.01239